Search details
1.
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Int J Cancer
; 139(4): 916-27, 2016 08 15.
Article
in English
| MEDLINE | ID: mdl-27037627
2.
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.
Immunol Cell Biol
; 94(5): 470-8, 2016 05.
Article
in English
| MEDLINE | ID: mdl-26743033
3.
The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.
Int J Cancer
; 137(11): 2729-38, 2015 Dec 01.
Article
in English
| MEDLINE | ID: mdl-26041304
4.
Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.
Cancer Immunol Immunother
; 64(12): 1575-86, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26472728
5.
Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Br J Haematol
; 164(2): 251-7, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24164493
6.
Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins.
Br J Haematol
; 183(2): 313-317, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29048126
7.
Fucosylation and Sialylation of Fc-Fragment of anti-Tumour Necrosis Factor Alpha Antibodies do not Influence Their Immunogenicity in Monocyte-Derived Dendritic Cells.
J Crohns Colitis
; 15(9): 1596-1601, 2021 Sep 25.
Article
in English
| MEDLINE | ID: mdl-33631789
8.
Human MAP Tau Based Targeted Cytolytic Fusion Proteins.
Biomedicines
; 5(3)2017 Jun 27.
Article
in English
| MEDLINE | ID: mdl-28653985
9.
Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology.
Anticancer Agents Med Chem
; 17(10): 1434-1440, 2017.
Article
in English
| MEDLINE | ID: mdl-28270070
10.
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Cancer Lett
; 372(2): 201-9, 2016 Mar 28.
Article
in English
| MEDLINE | ID: mdl-26806809
11.
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Oncotarget
; 7(41): 67166-67174, 2016 Oct 11.
Article
in English
| MEDLINE | ID: mdl-27564103
12.
Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies.
MAbs
; 7(5): 853-62, 2015.
Article
in English
| MEDLINE | ID: mdl-26218624
13.
Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein.
Cancer Lett
; 365(2): 149-55, 2015 Sep 01.
Article
in English
| MEDLINE | ID: mdl-25888452
14.
Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
MAbs
; 6(5): 1283-9, 2014.
Article
in English
| MEDLINE | ID: mdl-25517313
15.
A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues.
Cancer Lett
; 352(2): 228-35, 2014 Oct 01.
Article
in English
| MEDLINE | ID: mdl-25016058
16.
EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
Mol Cancer Ther
; 13(9): 2194-202, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24980949
17.
Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
Cancer Lett
; 341(2): 178-85, 2013 Dec 01.
Article
in English
| MEDLINE | ID: mdl-23973499
18.
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.
Toxins (Basel)
; 4(9): 676-94, 2012 09.
Article
in English
| MEDLINE | ID: mdl-23105975
19.
Asymmetric reduction of ketones with recombinant E. coli whole cells in neat substrates.
Chem Commun (Camb)
; 47(44): 12230-2, 2011 Nov 28.
Article
in English
| MEDLINE | ID: mdl-22005469
Results
1 -
19
de 19
1
Next >
>>